Medpace (NASDAQ:MEDP) Updates FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 17.250-17.950 for the period, compared to the consensus earnings per share estimate of 17.070. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Medpace Stock Down 0.7%

Shares of MEDP stock traded down $3.55 during trading hours on Wednesday, reaching $528.12. 517,068 shares of the company’s stock were exchanged, compared to its average volume of 352,269. Medpace has a fifty-two week low of $373.00 and a fifty-two week high of $628.92. The stock has a market capitalization of $15.08 billion, a P/E ratio of 33.19, a P/E/G ratio of 2.64 and a beta of 1.15. The business has a fifty day moving average price of $482.55 and a 200-day moving average price of $493.73.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace will post 17.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on MEDP shares. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and increased their target price for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. BMO Capital Markets cut their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $547.00 price target (up from $477.00) on shares of Medpace in a report on Wednesday, July 8th. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $469.50.

Insider Activity at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several large investors have recently modified their holdings of the business. Geneos Wealth Management Inc. raised its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Quarry LP acquired a new position in Medpace in the 3rd quarter worth $35,000. Greenline Wealth Management LLC acquired a new position in Medpace in the 4th quarter worth $55,000. Group One Trading LLC increased its holdings in Medpace by 120.0% during the 4th quarter. Group One Trading LLC now owns 100 shares of the company’s stock worth $56,000 after purchasing an additional 600 shares in the last quarter. Finally, Johnson Financial Group Inc. increased its holdings in Medpace by 115.7% during the 3rd quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock worth $57,000 after purchasing an additional 59 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.